Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent a major breakthrough for patients with metastatic lung adenocarcinoma primarily exhibiting an EGFR-activating oncogenic mutation. The ability of EGFR inhibitors to block specific molecular pathways driving uncontrolled cellular division in cancer has resulted in a decreased incidence of serious systemic adverse events commonly associated with conventional cytotoxic chemotherapy. However, due to the abundant expression of EGFR in the skin and adnexal structures, cutaneous adverse events (CAEs) to EGFR inhibitors are frequent (1).